Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Palvella Therapeutics Announces Pricing of Upsized Public Offering
Palvella Therapeutics (PVLA) had its price target raised by Mizuho from $205.00 to $250.00. They now have an "outperform" rating on the stock.
Palvella Therapeutics (PVLA) had its price target raised by BTIG Research from $192.00 to $215.00. They now have a "buy" rating on the stock.
Palvella Therapeutics (PVLA) was given a new $210.00 price target by Truist Financial Corporation.